Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme reports revenues

Genzyme (NASDAQ:GENZ) reported fourth quarter and 2007 revenues slightly above the Street's estimates. The company also reiterated

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE